These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31859201)

  • 1. Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis.
    Nnaji CA; Shey MS; Adetokunboh OO; Wiysonge CS
    Vaccine; 2020 Feb; 38(6):1291-1301. PubMed ID: 31859201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Juan-Giner A; Namulwana ML; Kimathi D; Grantz KH; Fall G; Dia M; Bob NS; Sall AA; Nerima C; Sahani MK; Mulogo EM; Ampeire I; Hombach J; Nanjebe D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet Infect Dis; 2023 Aug; 23(8):965-973. PubMed ID: 37127047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
    Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Kimathi D; Juan-Giner A; Orindi B; Grantz KH; Bob NS; Cheruiyot S; Hamaluba M; Kamau N; Fall G; Dia M; Mosobo M; Moki F; Kiogora K; Chirro O; Thiong'o A; Mwendwa J; Guantai A; Karanja HK; Gitonga J; Mugo D; Ramko K; Faye O; Sanders EJ; Grais RF; Bejon P; Warimwe GM
    Lancet Infect Dis; 2023 Aug; 23(8):974-982. PubMed ID: 37127045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
    Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
    N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractional-dose yellow fever vaccination: an expert review.
    Roukens AHE; Visser LG
    J Travel Med; 2019 Sep; 26(6):. PubMed ID: 30937437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
    Roukens AHE; van Halem K; de Visser AW; Visser LG
    Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
    Tonacio AC; do Nascimento Pedrosa T; Borba EF; Aikawa NE; Pasoto SG; Filho JCRF; Sampaio Barros MM; Leon EP; Lombardi SCFS; Junior AM; Azevedo AS; Schwarcz WD; Fuller R; Yuki EFN; Ugolini Lopes MR; Rodrigues Pereira RM; Sampaio Barros PD; de Andrade DCO; de Medeiros-Ribeiro AC; de Moraes JCB; Shinjo SK; Miossi R; da Silva Duarte AJ; Lopes MH; Kallás EG; Almeida da Silva CA; Bonfá E
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0010002. PubMed ID: 34843469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression.
    Ferrara P; Losa L; Mantovani LG; Ambrosioni J; Agüero F
    J Travel Med; 2024 Apr; 31(3):. PubMed ID: 38438165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractional dosing of yellow fever vaccine to extend supply: a modelling study.
    Wu JT; Peak CM; Leung GM; Lipsitch M
    Lancet; 2016 Dec; 388(10062):2904-2911. PubMed ID: 27837923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis.
    Mashunye TR; Ndwandwe DE; Dube KR; Shey M; Shelton M; Wiysonge CS
    Lancet Infect Dis; 2021 Aug; 21(8):1161-1174. PubMed ID: 33939958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study.
    Doshi RH; Mukadi PK; Casey RM; Kizito GM; Gao H; Nguete U B; Laven J; Sabi L; Kaba DK; Muyembe-Tamfum JJ; Hyde TB; Ahuka-Mundeke S; Staples JE
    Lancet Infect Dis; 2024 Jun; 24(6):611-618. PubMed ID: 38335976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
    Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
    Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis.
    Schnyder JL; de Jong HK; Bache BE; Schaumburg F; Grobusch MP
    Lancet Glob Health; 2024 Mar; 12(3):e445-e456. PubMed ID: 38272044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
    Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP
    Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
    Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
    Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractional-Dose Yellow Fever Vaccination - Advancing the Evidence Base.
    Vannice K; Wilder-Smith A; Hombach J
    N Engl J Med; 2018 Aug; 379(7):603-605. PubMed ID: 29995585
    [No Abstract]   [Full Text] [Related]  

  • 20. WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper - June 2013.
    World Health Organization
    Vaccine; 2017 Oct; 35(43):5751-5752. PubMed ID: 28689653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.